After setbacks related to serious adverse events 20 years ago, gene therapy is now coming back to the central stage worldwide. In the past few years, gene therapy has shown astonishing efficacy against genetic diseases and cancers. In history, China carried out the world’s second gene therapy clinical trial in 1991 for hemophilia B and approved the world’s first gene therapy product—Gendicine—in 2003. In recent years, numerous efforts have been made on gene editing. Here, researchers reviewed the past of gene therapy in China and highlighted recent advances. They also discussed the regulations and future perspectives of gene therapy in China.
For further information, see Gene Ther (https://www.nature.com/articles/s41434-020-0163-7)